All In Biotech

Drug Trial Radar · NCT03772678

A Phase I Study to Evaluate LSALT Peptide

A Phase I Double-blind, Placebo-controlled, Randomized, Single and Multiple Ascending Dose Finding Study to Evaluate the Safety and Pharmacokinetic Profile of LSALT Peptide in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Nov 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

52

Actual

Start

Jun 27, 2019

Primary completion

Mar 31, 2020

Study completion Mar 31, 2020

Sponsor

Lead sponsor
Arch Biopartners Inc.Industry
Sponsor type
Industry
First posted
Dec 11, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A phase I double-blind, placebo-controlled, randomized, single and multiple ascending dose finding study to evaluate the safety and pharmacokinetic profile of LSALT peptide in healthy participants

Conditions

  • None - Study is to Determine Safety in Healthy Participants

Interventions

  • LSALT peptideDrug

    novel 16 amino acid peptide

  • 0.9% SalineOther

    saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety EvaluationTime frame: Within 21 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network Ltd.

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.